Neue Entwicklungen zur Genetik und Therapie des Retinoblastoms

Abstract

Retinoblastomas are the most frequent primary malignant intraocular tumours worldwide. Conventional and new treatment modalities have significantly improved the chance for survival and preservation of vision. The armamentarium of treatment modalities has been broadened recently by new techniques like intraarterial chemotherapy, which still has to be considered as experimental since long-term follow-up results are not yet available. The excellent prognosis for retinoblastomas in countries with a well developed health system is contrasted by the miserable prognosis for retinoblastomas in developing countries, which must be changed by a joint effort of all centres.

Islet Co-Expression of CD133 and ABCB5 in Human Retinoblastoma Specimens

“…Choice of therapy is based on the International Intraocular Retinoblastoma Classification (IIRC) or the International Classification of Retinoblastoma (ICRB), which divides groups of different tumor expansion. As the most effective treatment option, enucleation remains the therapy of choice for patients with massive disease extent such as high-risk groups D or E according to IIRC and ICRB and in cases of failure of alternative therapies 1 , 5 , 6 , 8 9 10 11 12 13 . In a multicenter study, including 2854 eyes, primary enucleation was performed in 41.3%.…”